Experienced in Autoimmune Hemolytic Anemia

Dr. Mark A. Hoffman

Hematology | Oncology
2800 Marcus Avenue, 
New Hyde Park, NY 
On Staff At
Experienced in Autoimmune Hemolytic Anemia
2800 Marcus Avenue, 
New Hyde Park, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Hoffman is a Hematologist and an Oncologist in New Hyde Park, New York. Dr. Hoffman is rated as an Experienced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Breast Cancer, Endometrial Cancer, Adult Soft Tissue Sarcoma, and Inflammatory Breast Cancer.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
McGill University
Residency
Vancouver General Hospital
Specialties
Hematology
Oncology
Licenses
Internal Medicine in NY
Fellowships
Montefiore Medical Center-Moses Division
Albert Einstein College of Medicine-Yeshiva University
Hospital Affiliations
Long Island Jewish Medical Center
North Shore University Hospital
Languages Spoken
English
French
Hebrew
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northwell Health
  • INSURANCE PLAN
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

2800 Marcus Avenue, New Hyde Park, NY 11042

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
Enrollment Status: Completed
Publish Date: December 06, 2024
Intervention Type: Drug
Study Drugs: LEE-011, Fulvestrant
Study Phase: Phase 2
A Phase II Study of Pembrolizumab Combined With Pegylated Liposomal Doxorubicin (PLD) For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase II Study of Pembrolizumab Combined With Pegylated Liposomal Doxorubicin (PLD) For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Enrollment Status: Completed
Publish Date: September 13, 2022
Intervention Type: Drug
Study Drugs: Pembrolizumab, Pegylated Liposomal Doxorubicin
Study Phase: Phase 2
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer
Enrollment Status: Completed
Publish Date: March 08, 2022
Intervention Type: Drug
Study Drug: Bupropion Hydrochloride
Study Phase: Phase 2
View 2 Less Clinical Trials

4 Total Publications

Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Journal: Gynecologic oncology
Published: June 10, 2020
Similar Doctors
Elite in Autoimmune Hemolytic Anemia
Dr. Irina Murakhovskaya
Hematology Oncology | Hematology | Oncology
Elite in Autoimmune Hemolytic Anemia
Dr. Irina Murakhovskaya
Hematology Oncology | Hematology | Oncology

Montefiore Medical Center

111 E 210th St, 
Bronx, NY 
 (23.4 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Irina Murakhovskaya is a Hematologist Oncology specialist and a Hematologist in Bronx, New York. Dr. Murakhovskaya is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. Her top areas of expertise are Autoimmune Hemolytic Anemia, Thrombocytopenia, Adult Immune Thrombocytopenia, and Hemangioma Thrombocytopenia Syndrome.

Richard R. Furman
Distinguished in Autoimmune Hemolytic Anemia
Dr. Richard R. Furman
Hematology | Oncology
Distinguished in Autoimmune Hemolytic Anemia
Dr. Richard R. Furman
Hematology | Oncology

Weill Medical College Of Cornell

520 E 70th St, Suite 651, 
New York, NY 
 (32.2 miles away)
212-746-6575
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Furman is a Hematologist and an Oncologist in New York, New York. Dr. Furman is rated as an Elite provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Richter Syndrome, Bone Marrow Aspiration, and Lymphadenectomy.

Distinguished in Autoimmune Hemolytic Anemia
Dr. Bruce G. Raphael
Hematology Oncology | Hematology | Oncology
Distinguished in Autoimmune Hemolytic Anemia
Dr. Bruce G. Raphael
Hematology Oncology | Hematology | Oncology

New York University

240 E 38th St, 
New York, NY 
 (33.8 miles away)
212-263-7300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bruce Raphael is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Raphael is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Essential Thrombocythemia, Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hoffman's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 60 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile